This article was originally published in The Gray Sheet
Executive SummaryAd campaign for Intacs intrastromal corneal ring segments to treat mild nearsightedness commences the week of May 15 in 20 U.S. cities. The device gained FDA approval last year (1"The Gray Sheet" April 19, 1999, p. 12). The company plans to spend up to $5 mil. for radio, print and direct mail ads in the consumer campaign, the company says in a May 18 release
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.